Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Hemato Oncology Testing Market Size, Value And Growth Trajectory Through 2030#_x000D_
The hemato oncology testing market size has experienced rapid growth in recent years. It is projected to expand from $3.93 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.4%. This historic growth can be attributed to several factors including the rising incidence of blood cancers, the expansion of hospital diagnostic laboratories, increasing awareness of early cancer detection, a surge in clinical research activities, and the availability of advanced testing reagents._x000D_
_x000D_
The hemato oncology testing market is poised for significant expansion in the coming years. This market is projected to reach $7.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.6%. This anticipated growth during the forecast period is fueled by factors such as the increasing adoption of precision oncology diagnostics, growing investments in genomic testing infrastructure, the expansion of AI-driven diagnostic platforms, the rising demand for companion diagnostics, and ongoing innovation in assay technologies. Key trends characterizing this period encompass the increasing uptake of molecular diagnostic testing, the expanding utilization of next-generation sequencing in oncology, the escalating demand for personalized cancer diagnostics, the proliferation of automated laboratory testing platforms, and the improved integration of data analytics within hemato-oncology._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Hemato Oncology Testing Market Growth Factors Behind Sustained Expansion#_x000D_
The hemato oncology testing market is anticipated to expand due to the growing occurrence of hematologic cancer. Hematologic cancer describes a category of cancers that originate in the blood, affecting the blood, bone marrow, and lymphatic system, and includes diseases such as leukemia, lymphoma, and myeloma. Early diagnosis, which can be accomplished through hemato oncology testing, is vital for reducing the impact of these diseases. As an illustration, in September 2025, Cancer Research UK, a UK-based charity, indicated that from 2024 to 2026, the incidence rate of leukemia in the UK is estimated to be approximately 17.9 cases per 100,000 people per year, with a projected decrease of 3% to about 17.4 per 100,000 by 2038 to 2040. Therefore, the rising incidence of hematologic cancer is a significant factor driving the growth of the hemato-oncology testing market._x000D_
_x000D_
#Hemato Oncology Testing Market Segment Performance And Emerging Opportunities#_x000D_
The hemato oncology testing market covered in this report is segmented – _x000D_
_x000D_
1) By Product And Services: Assay Kits And Reagents, Services_x000D_
2) By Cancer Type: Leukemia, Lymphoma, Multiple Myeloma_x000D_
3) By Technology: Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS)_x000D_
4) By End User: Hospitals, Academic And Research Institutes_x000D_
_x000D_
Subsegments:_x000D_
1) By Assay Kits And Reagents: PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies_x000D_
2) By Services: Testing Services, Data Analysis Services_x000D_
_x000D_
#Hemato Oncology Testing Market Industry Trends Fueling Future Revenue Growth#_x000D_
Leading companies within the hemato-oncology testing market are introducing advancements such as next-generation sequencing (NGS) to enhance the precision and speed of genetic analysis, enable thorough profiling of hematologic cancers, and support customized treatment approaches aligned with individual patient requirements. Next-generation sequencing (NGS) represents a high-throughput DNA sequencing method that facilitates the rapid and economical examination of entire genomes or specific DNA segments. A notable instance occurred in October 2024, when NeoGenomics Inc., a US-based entity specializing in cancer diagnostics and genomic testing, unveiled AML Express. This next-generation sequencing (NGS) tool is specifically designed for the swift identification of mutations linked to Acute Myeloid Leukemia (AML). This sophisticated diagnostic platform delivers superior accuracy and prompt results, thereby assisting oncologists in making well-timed, targeted therapeutic choices. AML Express aims to elevate patient outcomes by offering precise mutation insights relevant to AML-specific genetic profiles._x000D_
_x000D_
#Hemato Oncology Testing Market Industry Leaders And Competitive Landscape#_x000D_
Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health _x000D_
_x000D_
#View The Full Hemato Oncology Testing Market Report:#_x000D_
_x000D_
#Hemato Oncology Testing Market Regional Analysis And Top Geography#_x000D_
North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.